Replies to post #81531 on PharmaCyte Biotech Inc (PMCB)

[ace1234]

Sometimes you just have to slog through the mud. The end goal is to get into trials and that's what they're doing. It's slow & messy but they are moving one step at a time.

[DragonBear]

My perspective is one of bereavement.

Interesting perspective.

I think we all know PMCB is not a real biotech

Correct. It's a Microcrap biotech scam.

Seeing how the market reacts, what would have happened last year had they reported month after month about the setbacks?

As opposed to continuously cranking out PRs as though nothing was wrong. Then came the Nov update, and the revelation they ran into a series of problems.

it looks like it is the life's work of Lohr, Günzburg and Salmons. They never gave up on it and kept pushing (and are still doing preclinical trials for other applications)

Yes, they have a vested financial interest in Austrianova, being the founders, and exec officers. Why wouldn't they keep peddling their encapsulation method?

The storied history of Austrianova is they were formed in 2004. Unable to attract sufficient private equity funding, they still attempted to build manufacturing facilities in Singapore, and went bankrupt, as you state in 2008. Enter Nulivex, the forerunner of PMCB. When they buy SG Austria Pte. Ltd (headed by Gunzburg, Salmons) in Jul 2011. Apparently a subsidiary stub of SG Austria Group. Through 2011-2014 Gunzburg in particular was active in Nulivex, helping to arrange funds to flow from Nulivex to Austrianova Singapore. Surprise Austrianova able to announce completion of facilities in 2014. Austrianova scraped up funding from the Microcrap market through the back door.

he planned trial in Australia - please reread this PR - Abraxane has become the gold standard and was no more a suitable candidate for a comparator arm

Part of the gibberish Kenny pumped in 2016, while stating they expected an IND to be approved, with a CT starting by year's end. Sound familiar? Note this passage:

Understandably, we felt patients with pancreatic cancer would opt for the new ‘gold standard’ of care rather than enrolling in a clinical trial to prove that PharmaCyte’s treatment is superior to the gold standard.

Back then Kenny seems to have been peddling CIAB as a front line treatment. Here he's admitting recruiting patients is going to be difficult. He goes on with...

In addition, to prove success the originally designed trial would have involved hundreds of patients, taken years to complete and would have been so expensive to conduct that only “big pharma” could have afforded to carry it out successfully.

Well guess what- Kenny recently admitted the FDA wanted "hundreds of patients", or an estimated total of 240. So two yrs later, it's suddenly not that expensive after all, and won't take years? Some of Kenny's older PRs were sort of sloppy.

Other treatments trials underway don't scare me.

They would if PMCB were not a scam. Time to market is money. But for a Microcrap scam, elongating the time, so insiders can continue to dump stock is more important.

I am confident they will figure out the documentation as well

All they have to do is read the CFRs.

The more choices in terms of effectiveness, costs and side effects, the more hope for patients

And those choices will appear in the market. Meanwhile Kenny will be promising an IND any month/year now.